美国 · SEC FORM 4
ORAMED PHARMACEUTICALS INC.
ORMP · Nasdaq · CIK 0001176309 · Healthcare · Biotechnology
内部人信号
0 qualifying P purchase groups
当前 180 天评分窗口
12 同一窗口内观察到的 Form 4 交易行
4 sales · 8 期权、代扣税、授予、赠与或其他交易行
为什么没有活跃信号？
评分构成
活跃窗口内没有合资格买入，因此不计算分数。缺失的输入不会被当作零分或看空信号。
为什么没有分数？
- 没有合资格公开市场买入可提供聚集度、规模、角色、近期性或确信度输入。
- 卖出及其他 Form 4 活动继续作为背景显示，不会形成负分。
卖出和其他 Form 4 活动会单独显示，不会形成负面买入信号。没有买入不会被评分为看空。
内部人活动时间轴
申报人轨道展示最近 180 天。符号形状区分交易类型；卖出仅作为背景。
—
买方广度、集中度与聚集买入
合资格买入进入 180 天研究窗口后，这些模块才会启用。
信号历史
Scores are archived only when the company qualifies for a published US buy-signal snapshot. 最近一次合资格买入: 2023-04-04 · Mayer Arie.
近期 Form 4 活动
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
市场背景
该股票尚未获取市场背景。每日任务会轮转处理美国股票池。
空头余额
空头余额是券商向 FINRA 申报的外部背景数据，不影响内部人信号。
- 空头股数
- 1,433,436
- 上期报告
- 1,307,745
- 日均成交量
- 195,596
- 回补天数
- 7.3
FINRA 结算日：2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数，每月两个结算日之后约一周公布；不是占已发行股份的比例。
历史股票买入
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2023-04-04 | Mayer Arie | 买入 (P) | Common Stock | 3,800 | USD 2.21 | USD 8,398 | SEC 申报 ↗ |
| 2023-04-03 | Mayer Arie | 买入 (P) | Common Stock | 5,009 | USD 2.22 | USD 11,120 | SEC 申报 ↗ |
| 2023-03-16 | KIDRON NADAV | 买入 (P) | Common Stock | 26,000 | USD 2.04 | USD 53,040 | SEC 申报 ↗ |
| 2023-03-14 | Rozov Yadin | 买入 (P) | Common Stock | 50,000 | USD 2.05 | USD 102,500 | SEC 申报 ↗ |
| 2023-03-14 | KIDRON NADAV | 买入 (P) | Common Stock | 100,000 | USD 2.01 | USD 201,000 | SEC 申报 ↗ |
| 2023-03-13 | Rozov Yadin | 买入 (P) | Common Stock | 20,000 | USD 1.96 | USD 39,200 | SEC 申报 ↗ |
Form 4 申报证据
40 transaction lines in the latest 365-day window; 176 in local history.
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-10-01 | Hexter Joshua | 卖出 (S) | Common Stock | 30,000 | USD 4.51 | USD 135,330 | SEC 申报 ↗ |
| 2026-10-01 | Gabay Avraham | 卖出 (S) | Common Stock | 20,000 | USD 4.51 | USD 90,200 | SEC 申报 ↗ |
| 2026-09-24 | Kidron Miriam | 奖励／授予 (A) | Common Stock | 417,416 | USD — | USD — | SEC 申报 ↗ |
展开近期 Form 4 证据 (29 grouped rows)
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-10-01 | Hexter Joshua | 卖出 (S) | Common Stock | 30,000 | USD 4.51 | USD 135,330 | SEC 申报 ↗ |
| 2026-10-01 | Gabay Avraham | 卖出 (S) | Common Stock | 20,000 | USD 4.51 | USD 90,200 | SEC 申报 ↗ |
| 2026-09-24 | Kidron Miriam | 奖励／授予 (A) | Common Stock | 417,416 | USD — | USD — | SEC 申报 ↗ |
| 2026-09-24 | KIDRON NADAV | 奖励／授予 (A) | Common Stock | 718,262 | USD — | USD — | SEC 申报 ↗ |
| 2026-09-24 | Hexter Joshua | 奖励／授予 (A) | Common Stock | 284,746 | USD — | USD — | SEC 申报 ↗ |
| 2026-09-24 | Gabay Avraham | 奖励／授予 (A) | Common Stock | 209,291 | USD — | USD — | SEC 申报 ↗ |
| 2026-07-02 | Hexter Joshua | 期权行权／转换 (M) | Common Stock | 50,000 | USD 3.69 | USD 184,500 | SEC 申报 ↗ |
| 2026-07-01 | Hexter Joshua | 卖出 (S) | Common Stock | 137,000 | USD 4.46 | USD 611,020 | SEC 申报 ↗ |
| 2026-07-01 | Gabay Avraham | 卖出 (S) | Common Stock | 73,360 | USD 4.51 | USD 330,854 | SEC 申报 ↗ |
| 2026-03-30 | Kidron Miriam | 代扣税 (F) | Common Stock | 435,084 | USD 3.31 | USD 1,440,128 | SEC 申报 ↗ |
| 2026-03-30 | KIDRON NADAV | 代扣税 (F) | Common Stock | 44,818 | USD 3.31 | USD 148,348 | SEC 申报 ↗ |
| 2026-03-17 | Kidron Miriam | 奖励／授予 (A) | Common Stock | 119,558 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-03-17 | KIDRON NADAV | 奖励／授予 (A) | Common Stock | 167,005 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-03-17 | Hexter Joshua | 奖励／授予 (A) | Common Stock | 95,889 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-03-17 | Gabay Avraham | 奖励／授予 (A) | Common Stock | 95,889 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-03-12 | KIDRON NADAV | 赠与 (G) | Common Stock | 100,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-01-22 | Kidron Miriam | 期权行权／转换 (M) | Common Stock | 19,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-01-22 | KIDRON NADAV | 期权行权／转换 (M) | Common Stock | 109,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-01-22 | Hexter Joshua | 期权行权／转换 (M) | Common Stock | 19,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-01-22 | Gabay Avraham | 期权行权／转换 (M) | Common Stock | 19,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-01-14 | Kidron Miriam | 赠与 (G) | Common Stock | 86,166 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2025-12-31 | Shapiro Benjamin | 奖励／授予 (A) | Common Stock | 33,500 | USD — | USD — | SEC 申报 ↗ |
| 2025-12-31 | Reznick Yehuda | 奖励／授予 (A) | Common Stock | 36,250 | USD — | USD — | SEC 申报 ↗ |
| 2025-12-31 | Mayer Arie | 奖励／授予 (A) | Common Stock | 34,900 | USD — | USD — | SEC 申报 ↗ |
| 2025-12-31 | Kidron Miriam | 奖励／授予 (A) | Common Stock | 236,331 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2025-12-31 | KIDRON NADAV | 奖励／授予 (A) | Common Stock | 559,640 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2025-12-31 | Hexter Joshua | 奖励／授予 (A) | Common Stock | 212,328 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2025-12-31 | Gabay Avraham | 奖励／授予 (A) | Common Stock | 196,216 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2025-12-31 | Aghion Daniel | 奖励／授予 (A) | Common Stock | 36,250 | USD — | USD — | SEC 申报 ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
快照与身份
| 快照日期 | 2026-10-18 |
|---|---|
| 排名版本 | US-v1.2 |
| 数据质量 | PASS ELIGIBLE · — |
| 股票代码 | ORMP |
| CIK | 0001176309 |
| 行业 | Healthcare |
| 细分行业 | Biotechnology Yahoo Finance |
| SEC SIC | 2834 Pharmaceutical Preparations |
| 交易所 | Nasdaq |
数据覆盖
| 本地 Form 4 历史 | 176 transaction lines from 2021-02-26 to 2026-10-01 6 P purchase lines · 12 S sale lines · 158 other lines |
|---|---|
| SEC 公司申报 | 打开 SEC 申报 ↗ |
Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.